FatPenguin的个人主页 - 老虎社区

FatPenguin

FatPenguin

暂无个人介绍

IP属地：海外

2关注

0粉丝

0主题

0勋章

2021-12-23

Cool

Why Lucid Stock Jumped Today

2021-12-23

Cool

Gold steady as weaker dollar counters positive Omicron study impact

2021-12-23

Cool

Does This Wildly Accurate S&P 500 Ratio Signal Doom for Investors in 2022?

2021-12-23

Aapl

Amazon Stock: Why It Might Outperform Apple in 2022

2021-12-23

Cool

Grab Stock May Be Down But It Isn’t Out

2021-06-18

Moon

抱歉，原内容已删除

2021-06-17

Wtonks

Why a crash in meme stocks AMC and GameStop looks more likely now

2021-06-16

Solid

抱歉，原内容已删除

2021-06-15

Stonks

Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3574390258610228","uuid":"3574390258610228","gmtCreate":1611298110684,"gmtModify":1612615467725,"name":"FatPenguin","pinyin":"fatpenguin","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/61bcb8fe103d5050809234ff760d540b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":2,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.10%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"海外","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":691449079,"gmtCreate":1640232578472,"gmtModify":1640232578472,"author":{"id":"3574390258610228","authorId":"3574390258610228","name":"FatPenguin","avatar":"https://static.tigerbbs.com/61bcb8fe103d5050809234ff760d540b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574390258610228","authorIdStr":"3574390258610228"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691449079","repostId":"1140552564","repostType":4,"repost":{"id":"1140552564","pubTimestamp":1640225899,"share":"https://www.laohu8.com/m/news/1140552564?lang=&edition=full","pubTime":"2021-12-23 10:18","market":"us","language":"en","title":"Why Lucid Stock Jumped Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1140552564","media":"Motley Fool","summary":"What happened\nHot electric vehicle (EV) stockLucid Group(NASDAQ:LCID)seemed to have lost some of its","content":"<p>What happened</p>\n<p>Hot electric vehicle (EV) stock<b>Lucid Group</b>(NASDAQ:LCID)seemed to have lost some of its mojo in recent weeks. But it roared back on Wednesday, surging 1.79% today. Lucid shares just started trading on a popular stock index, and the luxury EV maker is now flush with cash to pump into growth. Oh, and Lucid Air received&nbsp;<i>yet another</i>&nbsp;glorious review that's called the car<b>Tesla</b>'s(NASDAQ:TSLA)\"living nightmare.\"</p>\n<p>So what</p>\n<p>On Dec. 20, Lucid stock started trading on the&nbsp;Nasdaq-100 index, a market-cap weighted index comprising 100 of the largest domestic and international non-financial stocks based on market capitalization.</p>\n<p>Inclusion in an index, especially a popular one like the Nasdaq-100 that's chock-full of growth stocks, can typically lift investor sentiment. But it can also drive the stock price higher as institutional investors who track the index have to buy the stock to match it. That's what's happening with Lucid stock right now, but it isn't the&nbsp;<i>only</i>&nbsp;factor driving the EV stock higher today.</p>\n<p>Lucid also announced it has completed the sale of senior convertible notes and raised roughly $2 billion in gross proceeds to use for general corporate purposes and business expansion.</p>\n<p>As of Sept. 30, 2021, Lucid had $4.8 billion in cash and cash equivalents, and short-term investments, which means Lucid now has almost $7 billion in cash to put to good use. Lucid had secured more than 17,000 reservations across all four trim variants of Lucid Air as of Nov. 15. Although the company is expected to deliver only a few hundred cars this year, Lucid has an ambitious target of producing 20,000 vehicles in 2022. The EV maker has evidently taken advantage of the market's enthusiasm by raising money while it can to scale up capacity.</p>\n<p>All of this comes right when the U.S. Environmental Protection Agency (EPA) has finalized its most ambitious-ever greenhouse gas-emission standards that&nbsp;hugely favor electric vehicles. On the basis of these new standards, the EPA projects sales of EVs and plug-in hybrids to grow 7% in model year 2023 to 17% by model year 2026.</p>\n<p>Meanwhile, Lucid Air Dream Edition -- the first and most expensive trim the company is selling -- continues to make heads turn. Popular YouTube channel&nbsp;<i>Throttle House</i>&nbsp;just released a detailed video review of Air Dream, comparing it to Tesla's Model S Plaid and concluding that Lucid could give Tesla a proper run for its money if it can successfully deploy Air Dream's powerful technology into lower-priced models.&nbsp;<i>Throttle House</i>&nbsp;calls Air Dream closest to the \"perfect EV\" we've seen so far.</p>\n<p>Now what</p>\n<p>Just yesterday, I picked Lucid as one of the&nbsp;hottest growth stocks primed to take off;the company is much-better placed than the likes of&nbsp;<b>Nikola</b>&nbsp;to navigate an ongoing probe by the Securities and Exchange Commission (SEC) given that its cars are already on the road and have been officially certified as being the longest range EV yet.</p>\n<p>I expect Lucid'sdelivery rate to be initially slow&nbsp;as it upgrades existing production lines. I also expect the company will continue to incur losses for a considerable period of time before it can convert revenues into profits. Yet, among all the EV stocks starting out, Lucid could&nbsp;potentially be one of the biggest EV stocks&nbsp;in the long run.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Lucid Stock Jumped Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Lucid Stock Jumped Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 10:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/why-lucid-stock-jumped-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nHot electric vehicle (EV) stockLucid Group(NASDAQ:LCID)seemed to have lost some of its mojo in recent weeks. But it roared back on Wednesday, surging 1.79% today. Lucid shares just ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/why-lucid-stock-jumped-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LCID":"Lucid Group Inc"},"source_url":"https://www.fool.com/investing/2021/12/22/why-lucid-stock-jumped-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140552564","content_text":"What happened\nHot electric vehicle (EV) stockLucid Group(NASDAQ:LCID)seemed to have lost some of its mojo in recent weeks. But it roared back on Wednesday, surging 1.79% today. Lucid shares just started trading on a popular stock index, and the luxury EV maker is now flush with cash to pump into growth. Oh, and Lucid Air received yet another glorious review that's called the carTesla's(NASDAQ:TSLA)\"living nightmare.\"\nSo what\nOn Dec. 20, Lucid stock started trading on the Nasdaq-100 index, a market-cap weighted index comprising 100 of the largest domestic and international non-financial stocks based on market capitalization.\nInclusion in an index, especially a popular one like the Nasdaq-100 that's chock-full of growth stocks, can typically lift investor sentiment. But it can also drive the stock price higher as institutional investors who track the index have to buy the stock to match it. That's what's happening with Lucid stock right now, but it isn't the only factor driving the EV stock higher today.\nLucid also announced it has completed the sale of senior convertible notes and raised roughly $2 billion in gross proceeds to use for general corporate purposes and business expansion.\nAs of Sept. 30, 2021, Lucid had $4.8 billion in cash and cash equivalents, and short-term investments, which means Lucid now has almost $7 billion in cash to put to good use. Lucid had secured more than 17,000 reservations across all four trim variants of Lucid Air as of Nov. 15. Although the company is expected to deliver only a few hundred cars this year, Lucid has an ambitious target of producing 20,000 vehicles in 2022. The EV maker has evidently taken advantage of the market's enthusiasm by raising money while it can to scale up capacity.\nAll of this comes right when the U.S. Environmental Protection Agency (EPA) has finalized its most ambitious-ever greenhouse gas-emission standards that hugely favor electric vehicles. On the basis of these new standards, the EPA projects sales of EVs and plug-in hybrids to grow 7% in model year 2023 to 17% by model year 2026.\nMeanwhile, Lucid Air Dream Edition -- the first and most expensive trim the company is selling -- continues to make heads turn. Popular YouTube channel Throttle House just released a detailed video review of Air Dream, comparing it to Tesla's Model S Plaid and concluding that Lucid could give Tesla a proper run for its money if it can successfully deploy Air Dream's powerful technology into lower-priced models. Throttle House calls Air Dream closest to the \"perfect EV\" we've seen so far.\nNow what\nJust yesterday, I picked Lucid as one of the hottest growth stocks primed to take off;the company is much-better placed than the likes of Nikola to navigate an ongoing probe by the Securities and Exchange Commission (SEC) given that its cars are already on the road and have been officially certified as being the longest range EV yet.\nI expect Lucid'sdelivery rate to be initially slow as it upgrades existing production lines. I also expect the company will continue to incur losses for a considerable period of time before it can convert revenues into profits. Yet, among all the EV stocks starting out, Lucid could potentially be one of the biggest EV stocks in the long run.","news_type":1},"isVote":1,"tweetType":1,"viewCount":738,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691440727,"gmtCreate":1640232570462,"gmtModify":1640232570462,"author":{"id":"3574390258610228","authorId":"3574390258610228","name":"FatPenguin","avatar":"https://static.tigerbbs.com/61bcb8fe103d5050809234ff760d540b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574390258610228","authorIdStr":"3574390258610228"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691440727","repostId":"2193150111","repostType":4,"repost":{"id":"2193150111","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640227636,"share":"https://www.laohu8.com/m/news/2193150111?lang=&edition=full","pubTime":"2021-12-23 10:47","market":"us","language":"en","title":"Gold steady as weaker dollar counters positive Omicron study impact","url":"https://stock-news.laohu8.com/highlight/detail?id=2193150111","media":"Reuters","summary":"Dec 23 (Reuters) - Gold prices held steady in holiday-thinned trade on Thursday, as a weaker dollar ","content":"<p>Dec 23 (Reuters) - Gold prices held steady in holiday-thinned trade on Thursday, as a weaker dollar offset renewed risk appetite fuelled by an encouraging Omicron study and increased optimism around the global economic outlook.</p>\n<p><b>FUNDAMENTALS</b></p>\n<p>Spot gold&nbsp;was little changed at $1,806.85 per ounce by 0218 GMT. U.S. gold futures&nbsp;were up 0.3% at $1,808.20.</p>\n<p>The metal was set for a second weekly gain at 0.5%.</p>\n<p>A South African study suggested reduced risks of hospitalisation and severe disease in people infected with the Omicron variant versus the Delta one.</p>\n<p>The United States on Wednesday authorised Pfizer Inc's&nbsp;antiviral COVID-19 pill for people aged 12 and older at risk of severe illness.</p>\n<p>U.S. stock indexes closed broadly higher overnight after investors cheered positive economic data and the White House said it was resuming talks on a massive social spending and climate change bill with a holdout senator.</p>\n<p>The dollar index&nbsp;hovered near a one-week low against riskier currencies and asset classes, making gold less expensive for holders of non-U.S. currencies.</p>\n<p>Investors took stock of data showing U.S. economic growth slowed sharply in the third quarter amid a flare-up in COVID-19 infections, although activity has since picked up, putting the economy on track to record its best performance this year since 1984.</p>\n<p>Spot silver&nbsp;was up 0.1% at $22.80 an ounce, platinum&nbsp;rose 0.3% to $968 and palladium&nbsp;fell 0.7% to $1,868.94.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gold steady as weaker dollar counters positive Omicron study impact</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGold steady as weaker dollar counters positive Omicron study impact\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-23 10:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 23 (Reuters) - Gold prices held steady in holiday-thinned trade on Thursday, as a weaker dollar offset renewed risk appetite fuelled by an encouraging Omicron study and increased optimism around the global economic outlook.</p>\n<p><b>FUNDAMENTALS</b></p>\n<p>Spot gold&nbsp;was little changed at $1,806.85 per ounce by 0218 GMT. U.S. gold futures&nbsp;were up 0.3% at $1,808.20.</p>\n<p>The metal was set for a second weekly gain at 0.5%.</p>\n<p>A South African study suggested reduced risks of hospitalisation and severe disease in people infected with the Omicron variant versus the Delta one.</p>\n<p>The United States on Wednesday authorised Pfizer Inc's&nbsp;antiviral COVID-19 pill for people aged 12 and older at risk of severe illness.</p>\n<p>U.S. stock indexes closed broadly higher overnight after investors cheered positive economic data and the White House said it was resuming talks on a massive social spending and climate change bill with a holdout senator.</p>\n<p>The dollar index&nbsp;hovered near a one-week low against riskier currencies and asset classes, making gold less expensive for holders of non-U.S. currencies.</p>\n<p>Investors took stock of data showing U.S. economic growth slowed sharply in the third quarter amid a flare-up in COVID-19 infections, although activity has since picked up, putting the economy on track to record its best performance this year since 1984.</p>\n<p>Spot silver&nbsp;was up 0.1% at $22.80 an ounce, platinum&nbsp;rose 0.3% to $968 and palladium&nbsp;fell 0.7% to $1,868.94.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"159934":"黄金ETF","518880":"黄金ETF","DUST":"二倍做空黄金矿业指数ETF-Direxion","GLD":"SPDR黄金ETF","IAU":"黄金信托ETF(iShares)","GDX":"黄金矿业ETF-VanEck","NUGT":"二倍做多黄金矿业指数ETF-Direxion"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193150111","content_text":"Dec 23 (Reuters) - Gold prices held steady in holiday-thinned trade on Thursday, as a weaker dollar offset renewed risk appetite fuelled by an encouraging Omicron study and increased optimism around the global economic outlook.\nFUNDAMENTALS\nSpot gold was little changed at $1,806.85 per ounce by 0218 GMT. U.S. gold futures were up 0.3% at $1,808.20.\nThe metal was set for a second weekly gain at 0.5%.\nA South African study suggested reduced risks of hospitalisation and severe disease in people infected with the Omicron variant versus the Delta one.\nThe United States on Wednesday authorised Pfizer Inc's antiviral COVID-19 pill for people aged 12 and older at risk of severe illness.\nU.S. stock indexes closed broadly higher overnight after investors cheered positive economic data and the White House said it was resuming talks on a massive social spending and climate change bill with a holdout senator.\nThe dollar index hovered near a one-week low against riskier currencies and asset classes, making gold less expensive for holders of non-U.S. currencies.\nInvestors took stock of data showing U.S. economic growth slowed sharply in the third quarter amid a flare-up in COVID-19 infections, although activity has since picked up, putting the economy on track to record its best performance this year since 1984.\nSpot silver was up 0.1% at $22.80 an ounce, platinum rose 0.3% to $968 and palladium fell 0.7% to $1,868.94.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691440459,"gmtCreate":1640232561983,"gmtModify":1640232561983,"author":{"id":"3574390258610228","authorId":"3574390258610228","name":"FatPenguin","avatar":"https://static.tigerbbs.com/61bcb8fe103d5050809234ff760d540b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574390258610228","authorIdStr":"3574390258610228"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691440459","repostId":"1164868978","repostType":4,"repost":{"id":"1164868978","pubTimestamp":1640229309,"share":"https://www.laohu8.com/m/news/1164868978?lang=&edition=full","pubTime":"2021-12-23 11:15","market":"us","language":"en","title":"Does This Wildly Accurate S&P 500 Ratio Signal Doom for Investors in 2022?","url":"https://stock-news.laohu8.com/highlight/detail?id=1164868978","media":"Motley Fool","summary":"While I'm generally skeptical of stock market indicators, investors might want to pay attention to this one.","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Predicting stock market performance is a near-impossible task.</li>\n <li>The Shiller P/E ratio may be as accurate an indicator as there is.</li>\n <li>But investors would still do well to focus on the long term.</li>\n</ul>\n<p>If someone ever asks me what I think the market is going to do next, I usually reply by saying I have no idea. I believe most investors would be wise to adopt this philosophy.</p>\n<p>This still doesn't prevent people from trying to forecast where things will go next. As investors, we want to appear like we know what the&nbsp;<b>S&amp;P 500</b>'s performance will be in the future. Then we can position our portfolios accordingly.</p>\n<p>But is there a data point out there that can signal with any level of accuracy what future returns will be? Read on to find out.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2869216c7d0cbc4c220f60d370cc7938\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>Not a bad&nbsp;indicator</b></p>\n<p>Every once in a while, I think the Shiller&nbsp;price-to-earnings(P/E) ratio, otherwise known as the cyclically adjusted P/E (CAPE) ratio, can provide a high-level view as to what prospective returns might be over the next decade.This&nbsp;metric is the P/E ratio of the S&amp;P 500 using the average net income of the previous 10 years, adjusted for inflation.</p>\n<p>If that sounds like a mouthful, don't worry. The objective of this data point is to smooth out any fluctuations in earnings. The highest it has ever been previously was in 1929 and 2000, and these times directly preceded bear markets. As you can see below, we are currently at the second highest level in history.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cd7fb9cd4886d330700f25d58806f67a\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>S&amp;P 500 SHILLER CAPE RATIO DATA BY YCHARTS.</span></p>\n<p>According to Advisor Perspectives, which provides news and commentary for financial advisors, the CAPE ratio explained an incredible 90% of the variation in returns from 1995 to 2020. In other words, for an asset class that's completely random, this is as accurate an indicator as we're going to get.</p>\n<p>The S&amp;P 500 has historically&nbsp;returned an average of 10% per year. But based on today's Shiller P/E ratio of 38, the market could be in for disappointing returns in 2022 and beyond.</p>\n<p>However, I don't think investors should panic just yet. The Great Recession of 2008 and 2009 and the coronavirus pandemic led to unprecedented amounts of government stimulus to support economic growth. Even with an elevated CAPE ratio over the past 10 years, the stock market just kept climbing higher. Credit the Federal Reserve for perhaps distorting the correlation between the Shiller P/E ratio and future returns.</p>\n<p><b>What should&nbsp;investors do?</b></p>\n<p>I firmly believe that you should only invest money in the stock market that you don't need for the next five years. This is because in the near term, the market is extremely unpredictable, but over longer time horizons, the probability of a positive return increases dramatically.</p>\n<p>With that in mind, if you're looking to put capital to work right now when interest rates are near zero, you really don't have any other option than to invest in the stock market. Although the Shiller P/E ratio might signal a poor decade of returns ahead, where else would you park your money?</p>\n<p>I believe that owning a well-diversified portfolio (at least 25 stocks) of competitively advantaged businesses that have proven track records and solid growth prospects is the best&nbsp;strategy&nbsp;you can pursue. Names like&nbsp;<b>Home Depot</b>&nbsp;(NYSE:HD)&nbsp;and&nbsp;<b>Starbucks</b>(NASDAQ:SBUX)immediately come to mind.</p>\n<p>The&nbsp;home-improvement giant&nbsp;has grown profits 16% annually over the past 10 years, is able to outshine competitors thanks to its massive scale, and still has huge expansion opportunities thanks to a robust U.S. housing market.</p>\n<p>The giant coffeehouse chain possesses a powerful brand, supported by a top-notch loyalty program and premium status that resonates strongly with consumers. Starbucks' management estimates that by 2030, there'll be a&nbsp;whopping 55,000&nbsp;locations worldwide, 63%&nbsp;higher&nbsp;than today's count.</p>\n<p><b>Focus on what really matters</b></p>\n<p>No matter what the Shiller P/E ratio says, I think Home Depot and Starbucks will continue to do well and be solid additions to anyone's portfolio. This is what investors must focus on. Concentrate intensely on the quality of the companies you own, and you'll surely do well over time.</p>\n<p>Trying to time the market based on whether you think it's cheap or expensive is not a game you want to play. Adding savings at regular intervals -- known as&nbsp;dollar-cost averaging-- reduces any biases you may have andallows you to improve your cost basis on stocks you buy.</p>\n<p>We're living in interesting times. There's still lots of uncertainty in the market today with no shortage of so-called experts telling us what we should do with our money. While the Shiller P/E ratio is a tool you can add to your investing arsenal, ignore the noise and keep your eyes on the long term.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Does This Wildly Accurate S&P 500 Ratio Signal Doom for Investors in 2022?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoes This Wildly Accurate S&P 500 Ratio Signal Doom for Investors in 2022?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 11:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/wildly-accurate-sp-500-ratio-signal-doom-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nPredicting stock market performance is a near-impossible task.\nThe Shiller P/E ratio may be as accurate an indicator as there is.\nBut investors would still do well to focus on the long ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/wildly-accurate-sp-500-ratio-signal-doom-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SBUX":"星巴克","HD":"家得宝",".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.fool.com/investing/2021/12/22/wildly-accurate-sp-500-ratio-signal-doom-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164868978","content_text":"Key Points\n\nPredicting stock market performance is a near-impossible task.\nThe Shiller P/E ratio may be as accurate an indicator as there is.\nBut investors would still do well to focus on the long term.\n\nIf someone ever asks me what I think the market is going to do next, I usually reply by saying I have no idea. I believe most investors would be wise to adopt this philosophy.\nThis still doesn't prevent people from trying to forecast where things will go next. As investors, we want to appear like we know what the S&P 500's performance will be in the future. Then we can position our portfolios accordingly.\nBut is there a data point out there that can signal with any level of accuracy what future returns will be? Read on to find out.\nIMAGE SOURCE: GETTY IMAGES.\nNot a bad indicator\nEvery once in a while, I think the Shiller price-to-earnings(P/E) ratio, otherwise known as the cyclically adjusted P/E (CAPE) ratio, can provide a high-level view as to what prospective returns might be over the next decade.This metric is the P/E ratio of the S&P 500 using the average net income of the previous 10 years, adjusted for inflation.\nIf that sounds like a mouthful, don't worry. The objective of this data point is to smooth out any fluctuations in earnings. The highest it has ever been previously was in 1929 and 2000, and these times directly preceded bear markets. As you can see below, we are currently at the second highest level in history.\nS&P 500 SHILLER CAPE RATIO DATA BY YCHARTS.\nAccording to Advisor Perspectives, which provides news and commentary for financial advisors, the CAPE ratio explained an incredible 90% of the variation in returns from 1995 to 2020. In other words, for an asset class that's completely random, this is as accurate an indicator as we're going to get.\nThe S&P 500 has historically returned an average of 10% per year. But based on today's Shiller P/E ratio of 38, the market could be in for disappointing returns in 2022 and beyond.\nHowever, I don't think investors should panic just yet. The Great Recession of 2008 and 2009 and the coronavirus pandemic led to unprecedented amounts of government stimulus to support economic growth. Even with an elevated CAPE ratio over the past 10 years, the stock market just kept climbing higher. Credit the Federal Reserve for perhaps distorting the correlation between the Shiller P/E ratio and future returns.\nWhat should investors do?\nI firmly believe that you should only invest money in the stock market that you don't need for the next five years. This is because in the near term, the market is extremely unpredictable, but over longer time horizons, the probability of a positive return increases dramatically.\nWith that in mind, if you're looking to put capital to work right now when interest rates are near zero, you really don't have any other option than to invest in the stock market. Although the Shiller P/E ratio might signal a poor decade of returns ahead, where else would you park your money?\nI believe that owning a well-diversified portfolio (at least 25 stocks) of competitively advantaged businesses that have proven track records and solid growth prospects is the best strategy you can pursue. Names like Home Depot (NYSE:HD) and Starbucks(NASDAQ:SBUX)immediately come to mind.\nThe home-improvement giant has grown profits 16% annually over the past 10 years, is able to outshine competitors thanks to its massive scale, and still has huge expansion opportunities thanks to a robust U.S. housing market.\nThe giant coffeehouse chain possesses a powerful brand, supported by a top-notch loyalty program and premium status that resonates strongly with consumers. Starbucks' management estimates that by 2030, there'll be a whopping 55,000 locations worldwide, 63% higher than today's count.\nFocus on what really matters\nNo matter what the Shiller P/E ratio says, I think Home Depot and Starbucks will continue to do well and be solid additions to anyone's portfolio. This is what investors must focus on. Concentrate intensely on the quality of the companies you own, and you'll surely do well over time.\nTrying to time the market based on whether you think it's cheap or expensive is not a game you want to play. Adding savings at regular intervals -- known as dollar-cost averaging-- reduces any biases you may have andallows you to improve your cost basis on stocks you buy.\nWe're living in interesting times. There's still lots of uncertainty in the market today with no shortage of so-called experts telling us what we should do with our money. While the Shiller P/E ratio is a tool you can add to your investing arsenal, ignore the noise and keep your eyes on the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":746,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691440576,"gmtCreate":1640232547862,"gmtModify":1640232547862,"author":{"id":"3574390258610228","authorId":"3574390258610228","name":"FatPenguin","avatar":"https://static.tigerbbs.com/61bcb8fe103d5050809234ff760d540b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574390258610228","authorIdStr":"3574390258610228"},"themes":[],"htmlText":"Aapl","listText":"Aapl","text":"Aapl","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691440576","repostId":"1102369438","repostType":4,"repost":{"id":"1102369438","pubTimestamp":1640230195,"share":"https://www.laohu8.com/m/news/1102369438?lang=&edition=full","pubTime":"2021-12-23 11:29","market":"us","language":"en","title":"Amazon Stock: Why It Might Outperform Apple in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1102369438","media":"TheStreet","summary":"Amazon and Apple are great companies, but AMZN stock could outperform its peer in 2022. Here are the","content":"<p>Amazon and Apple are great companies, but AMZN stock could outperform its peer in 2022. Here are the main reasons why.</p>\n<p>The stocks of tech giants Amazon&nbsp;and Apple&nbsp;both experienced incredible gains in 2020: AMZN climbed 76% while APPL slightly outperformed its competitor with an incredible 81% return. With AMZN trailing so far this year, I wonder: which will be the better stock to own in 2022?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ce27248fd6669a891a6b37c1d78953c9\" tg-width=\"976\" tg-height=\"549\" width=\"100%\" height=\"auto\"><span>Figure 1: Apple vs. Amazon.</span></p>\n<p><b>Amazon: cross-industry reach</b></p>\n<p>It’s not hard to see why Amazon could outperform Apple in 2022. The Seattle-based company has developed a dominant global presence, and not just in retail. Amazon operates very competitively in high-growth industries that range from e-commerce to cloud services and from tech devices to advertising and streaming services.</p>\n<p>Simply put, Amazon is a diversified tech giant that is growing revenues across all its business lines. The company continues to dominate online retail while also branching out into new emerging businesses, disrupting industries along the way.</p>\n<p><b>Amazon's innovation</b></p>\n<p>In addition to Amazon's dominance across multiple sectors, the tech company also continues to develop innovative products, such as its Echo and Alexa devices, which are quickly becoming a staple in many households. These products make it easier for Amazon to cross-sell their products and services, while increasing the total value of each transaction.</p>\n<p>In addition, Amazon has successfully diversified more deeply across its services portfolio — think cloud infrastructure and streaming, for example. I think this is another advantage that Amazon has over Apple, which is still working to monetize its existing customer base (although the Cupertino company has been increasingly successful at it).</p>\n<p><b>How high can AAPL go?</b></p>\n<p>In the end, the debate may boil down to price and valuation. AAPL has undergone a strong but unusual rally in late November and early December, even after an amazing two years of returns in 2020 and 2021 YTD. Against the tech-rich Nasdaq index, AAPL's performance in the month prior to December 13 had been the second-best in the past ten years:a staggering 19.5 percentage point&nbsp;advantage over the benchmark.</p>\n<p>True, the long-term bull thesis for Apple is compelling. Catalysts like the 5G-ready iPhone cycle and continued growth in the services segment could push the stock upwards in the foreseeable future. Apple should remain highly competitive in consumer tech devices and may soon become a key name in the metaverse. But how much of the upside potential to the stock may have already been priced in 2020 and 2021? Couldn’t 2022 be AMZN’s turn to shine?</p>\n<p><b>Conclusion</b></p>\n<p>In my view, Apple and Amazon are great companies, and the former deserves to be a part of a growth portfolio. But because AMZN stock has not rallied as much as AAPL has in the past few months, I believe shares of the cloud and e-commerce giant have a better chance of edging Apple in 2022.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon Stock: Why It Might Outperform Apple in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon Stock: Why It Might Outperform Apple in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 11:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/amazon/stock/why-amzn-could-outperform-aapl-in-2022><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amazon and Apple are great companies, but AMZN stock could outperform its peer in 2022. Here are the main reasons why.\nThe stocks of tech giants Amazon and Apple both experienced incredible gains in ...</p>\n\n<a href=\"https://www.thestreet.com/amazon/stock/why-amzn-could-outperform-aapl-in-2022\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"source_url":"https://www.thestreet.com/amazon/stock/why-amzn-could-outperform-aapl-in-2022","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102369438","content_text":"Amazon and Apple are great companies, but AMZN stock could outperform its peer in 2022. Here are the main reasons why.\nThe stocks of tech giants Amazon and Apple both experienced incredible gains in 2020: AMZN climbed 76% while APPL slightly outperformed its competitor with an incredible 81% return. With AMZN trailing so far this year, I wonder: which will be the better stock to own in 2022?\nFigure 1: Apple vs. Amazon.\nAmazon: cross-industry reach\nIt’s not hard to see why Amazon could outperform Apple in 2022. The Seattle-based company has developed a dominant global presence, and not just in retail. Amazon operates very competitively in high-growth industries that range from e-commerce to cloud services and from tech devices to advertising and streaming services.\nSimply put, Amazon is a diversified tech giant that is growing revenues across all its business lines. The company continues to dominate online retail while also branching out into new emerging businesses, disrupting industries along the way.\nAmazon's innovation\nIn addition to Amazon's dominance across multiple sectors, the tech company also continues to develop innovative products, such as its Echo and Alexa devices, which are quickly becoming a staple in many households. These products make it easier for Amazon to cross-sell their products and services, while increasing the total value of each transaction.\nIn addition, Amazon has successfully diversified more deeply across its services portfolio — think cloud infrastructure and streaming, for example. I think this is another advantage that Amazon has over Apple, which is still working to monetize its existing customer base (although the Cupertino company has been increasingly successful at it).\nHow high can AAPL go?\nIn the end, the debate may boil down to price and valuation. AAPL has undergone a strong but unusual rally in late November and early December, even after an amazing two years of returns in 2020 and 2021 YTD. Against the tech-rich Nasdaq index, AAPL's performance in the month prior to December 13 had been the second-best in the past ten years:a staggering 19.5 percentage point advantage over the benchmark.\nTrue, the long-term bull thesis for Apple is compelling. Catalysts like the 5G-ready iPhone cycle and continued growth in the services segment could push the stock upwards in the foreseeable future. Apple should remain highly competitive in consumer tech devices and may soon become a key name in the metaverse. But how much of the upside potential to the stock may have already been priced in 2020 and 2021? Couldn’t 2022 be AMZN’s turn to shine?\nConclusion\nIn my view, Apple and Amazon are great companies, and the former deserves to be a part of a growth portfolio. But because AMZN stock has not rallied as much as AAPL has in the past few months, I believe shares of the cloud and e-commerce giant have a better chance of edging Apple in 2022.","news_type":1},"isVote":1,"tweetType":1,"viewCount":675,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691440312,"gmtCreate":1640232510734,"gmtModify":1640232510734,"author":{"id":"3574390258610228","authorId":"3574390258610228","name":"FatPenguin","avatar":"https://static.tigerbbs.com/61bcb8fe103d5050809234ff760d540b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574390258610228","authorIdStr":"3574390258610228"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691440312","repostId":"1184389618","repostType":4,"repost":{"id":"1184389618","pubTimestamp":1640230223,"share":"https://www.laohu8.com/m/news/1184389618?lang=&edition=full","pubTime":"2021-12-23 11:30","market":"us","language":"en","title":"Grab Stock May Be Down But It Isn’t Out","url":"https://stock-news.laohu8.com/highlight/detail?id=1184389618","media":"InvestorPlace","summary":"When Southeast Asian ride-hailing and delivery company Grab Holdings(NASDAQ:GRAB) completed a revers","content":"<p>When Southeast Asian ride-hailing and delivery company&nbsp;<b>Grab Holdings</b>(NASDAQ:<b><u>GRAB</u></b>) completed a reverse merger with special purpose acquisition company Altimeter Growth Corp. in early December it made history as the largest company to go public via a SPAC merger. Yet, this didn’t stop GRAB stock from&nbsp;plummeting more than 20%&nbsp;on the day of the merger.</p>\n<p>Since then, investors have continued to give GRAB stock the cold shoulder, with shares falling another 16% to trade at $7.34 at the time of this writing.</p>\n<p>Now, before you write off an investment in Grab Holdings, consider that the company is still in the early innings and let’s consider where GRAB stock could go from here.</p>\n<p><b>What’s Behind Grab’s Cool Reception?</b></p>\n<p>Grab is the largest ride-hailing and delivery company in Southeast Asia, with&nbsp;operations in Singapore,&nbsp;Malaysia, Cambodia,&nbsp;Indonesia, Myanmar,&nbsp;Philippines,&nbsp;Thailand and Vietnam and serving more than 187 million users.</p>\n<p>There are a number of plausible explanations for why GRAB stock has not been well-received by investors.</p>\n<p>For starters, growth estimates for the Southeast Asian region have been lowered recently primarily due to the coronavirus pandemic. In September, the Asian Development Bank&nbsp;dropped its 2021 growth forecast&nbsp;for the region to 3.1% from 4.4% previously.</p>\n<p>Widespread lockdowns in the region due to recurring waves of COVID-19 have hurt demand for Grab’s ride-hailing services and weighed on revenue despite an increase in food-delivery volumes.</p>\n<p>Grab reported its&nbsp;third-quarter results&nbsp;on Nov. 11. Revenue fell 9% year over year to $157 million, with the company citing “a decline in mobility due to the severe lockdowns in Vietnam.” Falling revenue is obviously not something investors want to see, especially from a company that has yet to turn a profit.</p>\n<p>Yet, the company did report a 32% year-over-year increase in gross merchandise value, with the dollar value of transactions from Grab’s services rising to $4.04 billion thanks to strength in the company’s deliveries segment.</p>\n<p><b>There’s Reason for Optimism</b></p>\n<p>The deal to go public through the merger with Altimeter Growth Corp. valued Grab at close to $40 billion, which as I mentioned, was a record. The fact that three weeks later GRAB stock has a market cap of about $27.5 billion tells us that perhaps things got a bit too heated. However, there is reason for optimism.</p>\n<p>The ride-hailing platform has secured the backing of significant players across related industries, including&nbsp;<b>DiDi Global</b>(NYSE:<b><u>DIDI</u></b>),<b>Toyota</b>(NYSE:<b><u>TM</u></b>) and&nbsp;<b>SoftBank’s</b>(OTCMKTS:<b><u>SFTBY</u></b>) Vision Fund.</p>\n<p>Grab Holdings also has some positive catalysts on the horizon. For example, the company recently announced that it&nbsp;will be purchasing&nbsp;<b>Jaya Grocer</b>, a premium supermarket chain in Malaysia.</p>\n<p>This acquisition fits nicely with the ride-hailing and delivery business model the company seeks to expand. Management refers to the model as a “superapp” focus, whereby users can access multiple services in a single, convenient location.</p>\n<p><b>The Bottom Line on GRAB Stock</b></p>\n<p>I can’t say Grab Holdings can immediately turn things around. But its potential in the burgeoning Southeast Asian market means it remains relevant and has a long runway.</p>\n<p>Of the six analysts following GRAB stock, two rate it a “buy” and there are no “sell” ratings,according to&nbsp;<i>The Wall Street Journal</i>. Meanwhile, the consensus price target stands at $12.25, which represents upside of 67% from current levels.</p>\n<p>GRAB stock is very cheap now, so it’s hardly a dangerous speculative play. There’s a good argument to be made for investing now and hoping that the company continues to expand its footprint. Profitability should follow.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grab Stock May Be Down But It Isn’t Out</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrab Stock May Be Down But It Isn’t Out\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 11:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/grab-stock-may-be-down-but-it-isnt-out/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When Southeast Asian ride-hailing and delivery company Grab Holdings(NASDAQ:GRAB) completed a reverse merger with special purpose acquisition company Altimeter Growth Corp. in early December it made ...</p>\n\n<a href=\"https://investorplace.com/2021/12/grab-stock-may-be-down-but-it-isnt-out/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRAB":"Grab Holdings"},"source_url":"https://investorplace.com/2021/12/grab-stock-may-be-down-but-it-isnt-out/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184389618","content_text":"When Southeast Asian ride-hailing and delivery company Grab Holdings(NASDAQ:GRAB) completed a reverse merger with special purpose acquisition company Altimeter Growth Corp. in early December it made history as the largest company to go public via a SPAC merger. Yet, this didn’t stop GRAB stock from plummeting more than 20% on the day of the merger.\nSince then, investors have continued to give GRAB stock the cold shoulder, with shares falling another 16% to trade at $7.34 at the time of this writing.\nNow, before you write off an investment in Grab Holdings, consider that the company is still in the early innings and let’s consider where GRAB stock could go from here.\nWhat’s Behind Grab’s Cool Reception?\nGrab is the largest ride-hailing and delivery company in Southeast Asia, with operations in Singapore, Malaysia, Cambodia, Indonesia, Myanmar, Philippines, Thailand and Vietnam and serving more than 187 million users.\nThere are a number of plausible explanations for why GRAB stock has not been well-received by investors.\nFor starters, growth estimates for the Southeast Asian region have been lowered recently primarily due to the coronavirus pandemic. In September, the Asian Development Bank dropped its 2021 growth forecast for the region to 3.1% from 4.4% previously.\nWidespread lockdowns in the region due to recurring waves of COVID-19 have hurt demand for Grab’s ride-hailing services and weighed on revenue despite an increase in food-delivery volumes.\nGrab reported its third-quarter results on Nov. 11. Revenue fell 9% year over year to $157 million, with the company citing “a decline in mobility due to the severe lockdowns in Vietnam.” Falling revenue is obviously not something investors want to see, especially from a company that has yet to turn a profit.\nYet, the company did report a 32% year-over-year increase in gross merchandise value, with the dollar value of transactions from Grab’s services rising to $4.04 billion thanks to strength in the company’s deliveries segment.\nThere’s Reason for Optimism\nThe deal to go public through the merger with Altimeter Growth Corp. valued Grab at close to $40 billion, which as I mentioned, was a record. The fact that three weeks later GRAB stock has a market cap of about $27.5 billion tells us that perhaps things got a bit too heated. However, there is reason for optimism.\nThe ride-hailing platform has secured the backing of significant players across related industries, including DiDi Global(NYSE:DIDI),Toyota(NYSE:TM) and SoftBank’s(OTCMKTS:SFTBY) Vision Fund.\nGrab Holdings also has some positive catalysts on the horizon. For example, the company recently announced that it will be purchasing Jaya Grocer, a premium supermarket chain in Malaysia.\nThis acquisition fits nicely with the ride-hailing and delivery business model the company seeks to expand. Management refers to the model as a “superapp” focus, whereby users can access multiple services in a single, convenient location.\nThe Bottom Line on GRAB Stock\nI can’t say Grab Holdings can immediately turn things around. But its potential in the burgeoning Southeast Asian market means it remains relevant and has a long runway.\nOf the six analysts following GRAB stock, two rate it a “buy” and there are no “sell” ratings,according to The Wall Street Journal. Meanwhile, the consensus price target stands at $12.25, which represents upside of 67% from current levels.\nGRAB stock is very cheap now, so it’s hardly a dangerous speculative play. There’s a good argument to be made for investing now and hoping that the company continues to expand its footprint. Profitability should follow.","news_type":1},"isVote":1,"tweetType":1,"viewCount":662,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":168450877,"gmtCreate":1623981599499,"gmtModify":1634024776952,"author":{"id":"3574390258610228","authorId":"3574390258610228","name":"FatPenguin","avatar":"https://static.tigerbbs.com/61bcb8fe103d5050809234ff760d540b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574390258610228","authorIdStr":"3574390258610228"},"themes":[],"htmlText":"Moon","listText":"Moon","text":"Moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168450877","repostId":"1167804746","repostType":4,"isVote":1,"tweetType":1,"viewCount":37,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161327369,"gmtCreate":1623906268151,"gmtModify":1634026020023,"author":{"id":"3574390258610228","authorId":"3574390258610228","name":"FatPenguin","avatar":"https://static.tigerbbs.com/61bcb8fe103d5050809234ff760d540b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574390258610228","authorIdStr":"3574390258610228"},"themes":[],"htmlText":"Wtonks","listText":"Wtonks","text":"Wtonks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161327369","repostId":"1133173445","repostType":4,"repost":{"id":"1133173445","pubTimestamp":1623899282,"share":"https://www.laohu8.com/m/news/1133173445?lang=&edition=full","pubTime":"2021-06-17 11:08","market":"us","language":"en","title":"Why a crash in meme stocks AMC and GameStop looks more likely now","url":"https://stock-news.laohu8.com/highlight/detail?id=1133173445","media":"MarketWatch","summary":"Heavy insider selling is a warning sign that a stock’s price is inflated.\n\nCould insider sales of me","content":"<blockquote>\n Heavy insider selling is a warning sign that a stock’s price is inflated.\n</blockquote>\n<p>Could insider sales of meme stocks signal a coming crash in their share price? The empirical research suggests the answer is yes.</p>\n<p>The substantial stock sales by directors of GameStop GME, +0.21% and AMC Entertainment Holdings AMC, -6.54% didn’t surprise most rational investors. It’s clear that the current prices of these and other meme stocks are vastly inflated. In fact, investors should have seen AMC’s issuing new shares at its bloated price to raise capital as a warning sign.</p>\n<p>Critics might lambaste the opportunism of such insider selling, citing corporate governance gurus encouraging director ownership to align interests with public shareholders. But who can blame them? What is surprising is that more outside shareholders haven’t taken the signal to sell. It’s common for savvy investors to scan insider purchases and sales for signs of good or bad news ahead. Aggregate insider trading levels presage total stock returns for up to two years, according to the research of University of Michigan finance professor Nejat Seyhun, author of Investment Intelligence from Insider Trading.</p>\n<p>That said, some insider trades contain no signal at all, as directors buy when required to maintain mandatory ownership levels and sell when they need cash or to diversify investments. Moreover, insiders face reputational and legal risks when trading, so are careful not to signal hoarding good or bad news, lest they veer into unethical or illegal insider trading.</p>\n<p>But these meme-stock cases seem clearer. At AMC, for instance, many directors all sold around the same time in large numbers, near the company’s recent stock offering. Research by Durham University accounting professor Guanming He and colleagues indicates that the presence of concentrated insider stock-selling is associated with an increase in stock-price crash risk. That stands to reason: insiders know more than outsiders, whether investors, strategists or economists.</p>\n<p>Of course, no one can discern the fickle features of markets that precipitate reversals. But He’s research supports the view that insiders’ anticipation of future stock-price crash risk — from whatever source — does lead them to trim their holdings. In particular, the evidence is that insider sales are associated with 15-month-ahead crash risk.</p>\n<p>Such research may be particularly meaningful in the bizarre context of meme stocks. Compared to conventional stock trading, insiders are poised to make greater profits trading meme stocks and their trades are more informative given the greater degree of noise trading by uninformed traders.</p>\n<p>Research on past outcomes is no guarantee of future results, but together with common sense and an appreciation that all bubbles eventually burst, I’d be willing to place my own bets. The 15-month time frame would put the bursting of the GameStop bubble in the first quarter of 2022 and AMC around the third quarter. I’d certainly take both bets before I bought either stock.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why a crash in meme stocks AMC and GameStop looks more likely now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy a crash in meme stocks AMC and GameStop looks more likely now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 11:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/why-a-crash-in-meme-stocks-amc-and-gamestop-looks-more-likely-now-11623810848?siteid=yhoof2><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Heavy insider selling is a warning sign that a stock’s price is inflated.\n\nCould insider sales of meme stocks signal a coming crash in their share price? The empirical research suggests the answer is ...</p>\n\n<a href=\"https://www.marketwatch.com/story/why-a-crash-in-meme-stocks-amc-and-gamestop-looks-more-likely-now-11623810848?siteid=yhoof2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线","GME":"游戏驿站"},"source_url":"https://www.marketwatch.com/story/why-a-crash-in-meme-stocks-amc-and-gamestop-looks-more-likely-now-11623810848?siteid=yhoof2","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1133173445","content_text":"Heavy insider selling is a warning sign that a stock’s price is inflated.\n\nCould insider sales of meme stocks signal a coming crash in their share price? The empirical research suggests the answer is yes.\nThe substantial stock sales by directors of GameStop GME, +0.21% and AMC Entertainment Holdings AMC, -6.54% didn’t surprise most rational investors. It’s clear that the current prices of these and other meme stocks are vastly inflated. In fact, investors should have seen AMC’s issuing new shares at its bloated price to raise capital as a warning sign.\nCritics might lambaste the opportunism of such insider selling, citing corporate governance gurus encouraging director ownership to align interests with public shareholders. But who can blame them? What is surprising is that more outside shareholders haven’t taken the signal to sell. It’s common for savvy investors to scan insider purchases and sales for signs of good or bad news ahead. Aggregate insider trading levels presage total stock returns for up to two years, according to the research of University of Michigan finance professor Nejat Seyhun, author of Investment Intelligence from Insider Trading.\nThat said, some insider trades contain no signal at all, as directors buy when required to maintain mandatory ownership levels and sell when they need cash or to diversify investments. Moreover, insiders face reputational and legal risks when trading, so are careful not to signal hoarding good or bad news, lest they veer into unethical or illegal insider trading.\nBut these meme-stock cases seem clearer. At AMC, for instance, many directors all sold around the same time in large numbers, near the company’s recent stock offering. Research by Durham University accounting professor Guanming He and colleagues indicates that the presence of concentrated insider stock-selling is associated with an increase in stock-price crash risk. That stands to reason: insiders know more than outsiders, whether investors, strategists or economists.\nOf course, no one can discern the fickle features of markets that precipitate reversals. But He’s research supports the view that insiders’ anticipation of future stock-price crash risk — from whatever source — does lead them to trim their holdings. In particular, the evidence is that insider sales are associated with 15-month-ahead crash risk.\nSuch research may be particularly meaningful in the bizarre context of meme stocks. Compared to conventional stock trading, insiders are poised to make greater profits trading meme stocks and their trades are more informative given the greater degree of noise trading by uninformed traders.\nResearch on past outcomes is no guarantee of future results, but together with common sense and an appreciation that all bubbles eventually burst, I’d be willing to place my own bets. The 15-month time frame would put the bursting of the GameStop bubble in the first quarter of 2022 and AMC around the third quarter. I’d certainly take both bets before I bought either stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":56,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169277529,"gmtCreate":1623840919161,"gmtModify":1634027292493,"author":{"id":"3574390258610228","authorId":"3574390258610228","name":"FatPenguin","avatar":"https://static.tigerbbs.com/61bcb8fe103d5050809234ff760d540b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574390258610228","authorIdStr":"3574390258610228"},"themes":[],"htmlText":"Solid","listText":"Solid","text":"Solid","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169277529","repostId":"1166103542","repostType":4,"isVote":1,"tweetType":1,"viewCount":197,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187238484,"gmtCreate":1623754904248,"gmtModify":1634028978872,"author":{"id":"3574390258610228","authorId":"3574390258610228","name":"FatPenguin","avatar":"https://static.tigerbbs.com/61bcb8fe103d5050809234ff760d540b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574390258610228","authorIdStr":"3574390258610228"},"themes":[],"htmlText":"Stonks","listText":"Stonks","text":"Stonks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187238484","repostId":"1167457915","repostType":4,"repost":{"id":"1167457915","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623750756,"share":"https://www.laohu8.com/m/news/1167457915?lang=&edition=full","pubTime":"2021-06-15 17:52","market":"us","language":"en","title":"Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up","url":"https://stock-news.laohu8.com/highlight/detail?id=1167457915","media":"Benzinga","summary":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announ","content":"<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-15 17:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167457915","content_text":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.\nHere's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namelyPfizer Inc.PFE 0.05%-BioNTech SEBNTXandModerna, Inc.MRNA, both of which have authorized vaccines in the market.\nVaccine Type: Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.\nThe Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.\nThis spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.\nNovavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.\nThe Vaccine Doses: The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.\nThe interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.\nThe Target Population: The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.\nModerna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.\nSince then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.\nBothcompanieshave also initiated studies in the pediatric population.\nNovavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.\nVaccine Logistics: Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.\nPreviously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.\nNVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.\nVaccine Efficacy: Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.\nThe vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.\nModerna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.\nNovavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.\nAgainst variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.\nOverall efficacy was 90.4%, meeting the primary endpoint.\nCantor Fitzgerald On Novavax's Vaccine:A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.\n\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.\nShowing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.\nThis profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.\nVaccine Safety Data:Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.\nFor Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.\nPreliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.\nIn assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":187,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":691440312,"gmtCreate":1640232510734,"gmtModify":1640232510734,"author":{"id":"3574390258610228","authorId":"3574390258610228","name":"FatPenguin","avatar":"https://static.tigerbbs.com/61bcb8fe103d5050809234ff760d540b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574390258610228","idStr":"3574390258610228"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691440312","repostId":"1184389618","repostType":4,"isVote":1,"tweetType":1,"viewCount":662,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691440576,"gmtCreate":1640232547862,"gmtModify":1640232547862,"author":{"id":"3574390258610228","authorId":"3574390258610228","name":"FatPenguin","avatar":"https://static.tigerbbs.com/61bcb8fe103d5050809234ff760d540b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574390258610228","idStr":"3574390258610228"},"themes":[],"htmlText":"Aapl","listText":"Aapl","text":"Aapl","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691440576","repostId":"1102369438","repostType":4,"isVote":1,"tweetType":1,"viewCount":675,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691449079,"gmtCreate":1640232578472,"gmtModify":1640232578472,"author":{"id":"3574390258610228","authorId":"3574390258610228","name":"FatPenguin","avatar":"https://static.tigerbbs.com/61bcb8fe103d5050809234ff760d540b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574390258610228","idStr":"3574390258610228"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691449079","repostId":"1140552564","repostType":4,"isVote":1,"tweetType":1,"viewCount":738,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691440459,"gmtCreate":1640232561983,"gmtModify":1640232561983,"author":{"id":"3574390258610228","authorId":"3574390258610228","name":"FatPenguin","avatar":"https://static.tigerbbs.com/61bcb8fe103d5050809234ff760d540b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574390258610228","idStr":"3574390258610228"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691440459","repostId":"1164868978","repostType":4,"repost":{"id":"1164868978","pubTimestamp":1640229309,"share":"https://www.laohu8.com/m/news/1164868978?lang=&edition=full","pubTime":"2021-12-23 11:15","market":"us","language":"en","title":"Does This Wildly Accurate S&P 500 Ratio Signal Doom for Investors in 2022?","url":"https://stock-news.laohu8.com/highlight/detail?id=1164868978","media":"Motley Fool","summary":"While I'm generally skeptical of stock market indicators, investors might want to pay attention to this one.","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Predicting stock market performance is a near-impossible task.</li>\n <li>The Shiller P/E ratio may be as accurate an indicator as there is.</li>\n <li>But investors would still do well to focus on the long term.</li>\n</ul>\n<p>If someone ever asks me what I think the market is going to do next, I usually reply by saying I have no idea. I believe most investors would be wise to adopt this philosophy.</p>\n<p>This still doesn't prevent people from trying to forecast where things will go next. As investors, we want to appear like we know what the&nbsp;<b>S&amp;P 500</b>'s performance will be in the future. Then we can position our portfolios accordingly.</p>\n<p>But is there a data point out there that can signal with any level of accuracy what future returns will be? Read on to find out.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2869216c7d0cbc4c220f60d370cc7938\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>Not a bad&nbsp;indicator</b></p>\n<p>Every once in a while, I think the Shiller&nbsp;price-to-earnings(P/E) ratio, otherwise known as the cyclically adjusted P/E (CAPE) ratio, can provide a high-level view as to what prospective returns might be over the next decade.This&nbsp;metric is the P/E ratio of the S&amp;P 500 using the average net income of the previous 10 years, adjusted for inflation.</p>\n<p>If that sounds like a mouthful, don't worry. The objective of this data point is to smooth out any fluctuations in earnings. The highest it has ever been previously was in 1929 and 2000, and these times directly preceded bear markets. As you can see below, we are currently at the second highest level in history.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cd7fb9cd4886d330700f25d58806f67a\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"><span>S&amp;P 500 SHILLER CAPE RATIO DATA BY YCHARTS.</span></p>\n<p>According to Advisor Perspectives, which provides news and commentary for financial advisors, the CAPE ratio explained an incredible 90% of the variation in returns from 1995 to 2020. In other words, for an asset class that's completely random, this is as accurate an indicator as we're going to get.</p>\n<p>The S&amp;P 500 has historically&nbsp;returned an average of 10% per year. But based on today's Shiller P/E ratio of 38, the market could be in for disappointing returns in 2022 and beyond.</p>\n<p>However, I don't think investors should panic just yet. The Great Recession of 2008 and 2009 and the coronavirus pandemic led to unprecedented amounts of government stimulus to support economic growth. Even with an elevated CAPE ratio over the past 10 years, the stock market just kept climbing higher. Credit the Federal Reserve for perhaps distorting the correlation between the Shiller P/E ratio and future returns.</p>\n<p><b>What should&nbsp;investors do?</b></p>\n<p>I firmly believe that you should only invest money in the stock market that you don't need for the next five years. This is because in the near term, the market is extremely unpredictable, but over longer time horizons, the probability of a positive return increases dramatically.</p>\n<p>With that in mind, if you're looking to put capital to work right now when interest rates are near zero, you really don't have any other option than to invest in the stock market. Although the Shiller P/E ratio might signal a poor decade of returns ahead, where else would you park your money?</p>\n<p>I believe that owning a well-diversified portfolio (at least 25 stocks) of competitively advantaged businesses that have proven track records and solid growth prospects is the best&nbsp;strategy&nbsp;you can pursue. Names like&nbsp;<b>Home Depot</b>&nbsp;(NYSE:HD)&nbsp;and&nbsp;<b>Starbucks</b>(NASDAQ:SBUX)immediately come to mind.</p>\n<p>The&nbsp;home-improvement giant&nbsp;has grown profits 16% annually over the past 10 years, is able to outshine competitors thanks to its massive scale, and still has huge expansion opportunities thanks to a robust U.S. housing market.</p>\n<p>The giant coffeehouse chain possesses a powerful brand, supported by a top-notch loyalty program and premium status that resonates strongly with consumers. Starbucks' management estimates that by 2030, there'll be a&nbsp;whopping 55,000&nbsp;locations worldwide, 63%&nbsp;higher&nbsp;than today's count.</p>\n<p><b>Focus on what really matters</b></p>\n<p>No matter what the Shiller P/E ratio says, I think Home Depot and Starbucks will continue to do well and be solid additions to anyone's portfolio. This is what investors must focus on. Concentrate intensely on the quality of the companies you own, and you'll surely do well over time.</p>\n<p>Trying to time the market based on whether you think it's cheap or expensive is not a game you want to play. Adding savings at regular intervals -- known as&nbsp;dollar-cost averaging-- reduces any biases you may have andallows you to improve your cost basis on stocks you buy.</p>\n<p>We're living in interesting times. There's still lots of uncertainty in the market today with no shortage of so-called experts telling us what we should do with our money. While the Shiller P/E ratio is a tool you can add to your investing arsenal, ignore the noise and keep your eyes on the long term.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Does This Wildly Accurate S&P 500 Ratio Signal Doom for Investors in 2022?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoes This Wildly Accurate S&P 500 Ratio Signal Doom for Investors in 2022?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 11:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/22/wildly-accurate-sp-500-ratio-signal-doom-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nPredicting stock market performance is a near-impossible task.\nThe Shiller P/E ratio may be as accurate an indicator as there is.\nBut investors would still do well to focus on the long ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/22/wildly-accurate-sp-500-ratio-signal-doom-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SBUX":"星巴克","HD":"家得宝",".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.fool.com/investing/2021/12/22/wildly-accurate-sp-500-ratio-signal-doom-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164868978","content_text":"Key Points\n\nPredicting stock market performance is a near-impossible task.\nThe Shiller P/E ratio may be as accurate an indicator as there is.\nBut investors would still do well to focus on the long term.\n\nIf someone ever asks me what I think the market is going to do next, I usually reply by saying I have no idea. I believe most investors would be wise to adopt this philosophy.\nThis still doesn't prevent people from trying to forecast where things will go next. As investors, we want to appear like we know what the S&P 500's performance will be in the future. Then we can position our portfolios accordingly.\nBut is there a data point out there that can signal with any level of accuracy what future returns will be? Read on to find out.\nIMAGE SOURCE: GETTY IMAGES.\nNot a bad indicator\nEvery once in a while, I think the Shiller price-to-earnings(P/E) ratio, otherwise known as the cyclically adjusted P/E (CAPE) ratio, can provide a high-level view as to what prospective returns might be over the next decade.This metric is the P/E ratio of the S&P 500 using the average net income of the previous 10 years, adjusted for inflation.\nIf that sounds like a mouthful, don't worry. The objective of this data point is to smooth out any fluctuations in earnings. The highest it has ever been previously was in 1929 and 2000, and these times directly preceded bear markets. As you can see below, we are currently at the second highest level in history.\nS&P 500 SHILLER CAPE RATIO DATA BY YCHARTS.\nAccording to Advisor Perspectives, which provides news and commentary for financial advisors, the CAPE ratio explained an incredible 90% of the variation in returns from 1995 to 2020. In other words, for an asset class that's completely random, this is as accurate an indicator as we're going to get.\nThe S&P 500 has historically returned an average of 10% per year. But based on today's Shiller P/E ratio of 38, the market could be in for disappointing returns in 2022 and beyond.\nHowever, I don't think investors should panic just yet. The Great Recession of 2008 and 2009 and the coronavirus pandemic led to unprecedented amounts of government stimulus to support economic growth. Even with an elevated CAPE ratio over the past 10 years, the stock market just kept climbing higher. Credit the Federal Reserve for perhaps distorting the correlation between the Shiller P/E ratio and future returns.\nWhat should investors do?\nI firmly believe that you should only invest money in the stock market that you don't need for the next five years. This is because in the near term, the market is extremely unpredictable, but over longer time horizons, the probability of a positive return increases dramatically.\nWith that in mind, if you're looking to put capital to work right now when interest rates are near zero, you really don't have any other option than to invest in the stock market. Although the Shiller P/E ratio might signal a poor decade of returns ahead, where else would you park your money?\nI believe that owning a well-diversified portfolio (at least 25 stocks) of competitively advantaged businesses that have proven track records and solid growth prospects is the best strategy you can pursue. Names like Home Depot (NYSE:HD) and Starbucks(NASDAQ:SBUX)immediately come to mind.\nThe home-improvement giant has grown profits 16% annually over the past 10 years, is able to outshine competitors thanks to its massive scale, and still has huge expansion opportunities thanks to a robust U.S. housing market.\nThe giant coffeehouse chain possesses a powerful brand, supported by a top-notch loyalty program and premium status that resonates strongly with consumers. Starbucks' management estimates that by 2030, there'll be a whopping 55,000 locations worldwide, 63% higher than today's count.\nFocus on what really matters\nNo matter what the Shiller P/E ratio says, I think Home Depot and Starbucks will continue to do well and be solid additions to anyone's portfolio. This is what investors must focus on. Concentrate intensely on the quality of the companies you own, and you'll surely do well over time.\nTrying to time the market based on whether you think it's cheap or expensive is not a game you want to play. Adding savings at regular intervals -- known as dollar-cost averaging-- reduces any biases you may have andallows you to improve your cost basis on stocks you buy.\nWe're living in interesting times. There's still lots of uncertainty in the market today with no shortage of so-called experts telling us what we should do with our money. While the Shiller P/E ratio is a tool you can add to your investing arsenal, ignore the noise and keep your eyes on the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":746,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":169277529,"gmtCreate":1623840919161,"gmtModify":1634027292493,"author":{"id":"3574390258610228","authorId":"3574390258610228","name":"FatPenguin","avatar":"https://static.tigerbbs.com/61bcb8fe103d5050809234ff760d540b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574390258610228","idStr":"3574390258610228"},"themes":[],"htmlText":"Solid","listText":"Solid","text":"Solid","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169277529","repostId":"1166103542","repostType":4,"repost":{"id":"1166103542","pubTimestamp":1623835778,"share":"https://www.laohu8.com/m/news/1166103542?lang=&edition=full","pubTime":"2021-06-16 17:29","market":"us","language":"en","title":"Nio ET7 Will Be Equipped With 'High-Performance' LiDAR, Says Supplier","url":"https://stock-news.laohu8.com/highlight/detail?id=1166103542","media":"benzinga","summary":"Nio Inc’s LiDAR supplier Innovusion said on Wednesday it will equip the electric vehicle maker’s ET7","content":"<p><b>Nio Inc’s</b>&nbsp;LiDAR supplier Innovusion said on Wednesday it will equip the electric vehicle maker’s ET7 sedan with a \"high-performance product\" that can detect up to 500 meters, cnEV postreported.</p>\n<p><b>What Happened:</b>Bao Junwei, co-founder and Chief Executive Officer at Innovusion said its LiDAR technology works on the L3 and L4 autonomous driving and complements the L2 autonomous driving.</p>\n<p>Nio is expected to begin deliveries of its premium electric sedan ET7 in the first quarter of next year. The Chinese electric vehicle maker, which revealed ET7 earlier this year, is eyeing international expansion after establishing itself in China.</p>\n<p>Lidar, short for light detection and ranging sensors, uses laser light pulses to help vehicles perceive their surroundings. The technology is increasingly being seen as a key for automakers having self-driving ambitions.</p>\n<p><b>Price Action:</b>Nio shares closed 3% lower at $45.15 on Tuesday.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio ET7 Will Be Equipped With 'High-Performance' LiDAR, Says Supplier</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio ET7 Will Be Equipped With 'High-Performance' LiDAR, Says Supplier\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 17:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/06/21582411/nio-et7-will-be-equipped-with-high-performance-lidar-says-supplier><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nio Inc’s LiDAR supplier Innovusion said on Wednesday it will equip the electric vehicle maker’s ET7 sedan with a \"high-performance product\" that can detect up to 500 meters, cnEV postreported.\nWhat ...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582411/nio-et7-will-be-equipped-with-high-performance-lidar-says-supplier\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"source_url":"https://www.benzinga.com/news/21/06/21582411/nio-et7-will-be-equipped-with-high-performance-lidar-says-supplier","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166103542","content_text":"Nio Inc’s LiDAR supplier Innovusion said on Wednesday it will equip the electric vehicle maker’s ET7 sedan with a \"high-performance product\" that can detect up to 500 meters, cnEV postreported.\nWhat Happened:Bao Junwei, co-founder and Chief Executive Officer at Innovusion said its LiDAR technology works on the L3 and L4 autonomous driving and complements the L2 autonomous driving.\nNio is expected to begin deliveries of its premium electric sedan ET7 in the first quarter of next year. The Chinese electric vehicle maker, which revealed ET7 earlier this year, is eyeing international expansion after establishing itself in China.\nLidar, short for light detection and ranging sensors, uses laser light pulses to help vehicles perceive their surroundings. The technology is increasingly being seen as a key for automakers having self-driving ambitions.\nPrice Action:Nio shares closed 3% lower at $45.15 on Tuesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":197,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187238484,"gmtCreate":1623754904248,"gmtModify":1634028978872,"author":{"id":"3574390258610228","authorId":"3574390258610228","name":"FatPenguin","avatar":"https://static.tigerbbs.com/61bcb8fe103d5050809234ff760d540b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574390258610228","idStr":"3574390258610228"},"themes":[],"htmlText":"Stonks","listText":"Stonks","text":"Stonks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187238484","repostId":"1167457915","repostType":4,"repost":{"id":"1167457915","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623750756,"share":"https://www.laohu8.com/m/news/1167457915?lang=&edition=full","pubTime":"2021-06-15 17:52","market":"us","language":"en","title":"Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up","url":"https://stock-news.laohu8.com/highlight/detail?id=1167457915","media":"Benzinga","summary":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announ","content":"<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-15 17:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>It was \"better late than never\" for&nbsp;<b>Novavax, Inc.</b>NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.</p>\n<p>Here's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namely<b>Pfizer Inc.</b>PFE 0.05%-<b>BioNTech SE</b>BNTXand<b>Moderna, Inc.</b>MRNA, both of which have authorized vaccines in the market.</p>\n<p><b>Vaccine Type:</b>&nbsp;Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.</p>\n<p>The Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern&nbsp;vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.</p>\n<p>This spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.</p>\n<p>Novavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle&nbsp;that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.</p>\n<p><b>The Vaccine Doses:</b>&nbsp;The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.</p>\n<p>The interval between the two doses —&nbsp;the priming and booster dose —&nbsp;is 21 days each for Pfizer and Novavax and 28 days for Moderna.</p>\n<p><b>The Target Population:</b>&nbsp;The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants&nbsp;ages 16 years and older. The trial enrolled 43,448 participants.</p>\n<p>Moderna'sPhase 3 COVE study enrolled 30,000 participants&nbsp;ages 18 years and up.</p>\n<p>Since then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.</p>\n<p>Bothcompanieshave also initiated studies in the pediatric population.</p>\n<p>Novavax's study enrolled 29,960 participants&nbsp;18 years of age and older&nbsp;across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.</p>\n<p><b>Vaccine Logistics:</b>&nbsp;Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.</p>\n<p>Previously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five&nbsp;days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.</p>\n<p>NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.</p>\n<p><b>Vaccine Efficacy:</b>&nbsp;Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven&nbsp;days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.</p>\n<p>The vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.</p>\n<p>Moderna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.</p>\n<p>Novavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.</p>\n<p>Against variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.</p>\n<p>Overall efficacy was 90.4%, meeting the primary endpoint.</p>\n<p><b>Cantor Fitzgerald On Novavax's Vaccine:</b>A differentiating factor for NVX-2373&nbsp;is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.</p>\n<p>\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.</p>\n<p>Showing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.</p>\n<p>This profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.</p>\n<p><b>Vaccine Safety Data:</b>Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from&nbsp;BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.</p>\n<p>For Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.</p>\n<p>Preliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.</p>\n<p>In assessing reactogenicity seven&nbsp;days after dose one&nbsp;and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167457915","content_text":"It was \"better late than never\" for Novavax, Inc.NVAX, as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.\nHere's a comparative perspective of the vaccine candidates from Novavax, and the frontrunners, namelyPfizer Inc.PFE 0.05%-BioNTech SEBNTXandModerna, Inc.MRNA, both of which have authorized vaccines in the market.\nVaccine Type: Novavax's NVX-CoV2371 is a recombinant nano-particle protein-based COVID-19 vaccine that is packaged with the company's proprietary Matrix-M adjuvant.\nThe Pfizer-BioNTech and Moderna products are mRNA vaccines, or modern vaccines that work by using a genetic code called mRNA that instructs our immune cells to make spike protein, which is found on the surface of the virus that causes COVID-19.\nThis spike protein, though harmless, is capable of triggering our immune system to produce antibodies that offer protection against future infection.\nNovavax's vaccine is a protein adjuvant that contains the spike protein of the coronavirus itself, but formulated as a nanoparticle that cannot cause disease. The injected vaccine then stimulates the immune system to produce antibodies and T-cell immune responses.\nThe Vaccine Doses: The vaccines from each of the three companies require two doses. Each dose consists of 30 mcg for Pfizer and 100 mcg for Moderna, while for Novavax, each vaccine dose consists of 5 mcg of NVX-CoV2371 and 50 mcg of Matrix-M1 adjuvant that are co-formulated.\nThe interval between the two doses — the priming and booster dose — is 21 days each for Pfizer and Novavax and 28 days for Moderna.\nThe Target Population: The original late-stage trial of Pfizer-BioNTech evaluated the vaccine in participants ages 16 years and older. The trial enrolled 43,448 participants.\nModerna'sPhase 3 COVE study enrolled 30,000 participants ages 18 years and up.\nSince then, these two companies have obtained authorizations for their respective vaccines to be used in adolescents.\nBothcompanieshave also initiated studies in the pediatric population.\nNovavax's study enrolled 29,960 participants 18 years of age and older across 119 sites in the U.S. and Mexico. The placebo-controlled portion of PREVENT-19 continues in adolescents from 12 to less than 18 years of age and recently completed enrollment with 2,248 participants.\nVaccine Logistics: Pfizer recently secured FDA authorization for storing undiluted, thawed vaccine vials in the refrigerator at 2°C to 8°C for up to one month.\nPreviously, thawed, undiluted vaccine vials could be stored in the refrigerator for up to five days. Moderna's vaccine can be stored refrigerated between 2° and 8°C for up to 30 days prior to first use.\nNVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.\nVaccine Efficacy: Interim data from Pfizer-BioNTech's Phase 3 trials released in December showed the vaccine was well-tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection seven days or more after the second dose. Updated top-line results released for up to six months after the second dose confirmed efficacy at 91.3%.\nThe vaccine was found 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention, and 95.3% effective against severe COVID-19 as defined by the FDA. It was also proved effective against the U.K. strain in lab studies.\nModerna's vaccine showed efficacy of 94.1% against COVID-19. The company announced in May initial data from its Phase 2 study showing that a single 50 mcg dose of mRNA-1273 or mRNA-1273.351 given as a booster to previously vaccinated individuals increased neutralizing antibody titer responses against SARS-CoV-2 and two variants of concern, B.1.351, first identified in South Africa, and P.1, first identified in Brazil.\nNovavax's investigational vaccine demonstrated 100% protection against moderate and severe disease not involving variants of concern or variants of interest.\nAgainst variants of concern and variants of interest, the efficacy was 93.2% and in high-risk populations, defined as over 65 or under 65 years with certain comorbidities or having circumstances with frequent COVID-19 exposure, the efficacy was 91%.\nOverall efficacy was 90.4%, meeting the primary endpoint.\nCantor Fitzgerald On Novavax's Vaccine:A differentiating factor for NVX-2373 is that it showed vaccine efficacy of 93.2% against VoC/VoI, which demonstrates protection across a broad range of SARS-CoV-2 strains, Cantor Fitzgerald analyst Charles Duncan said in a Monday morning note.\n\"Overall, these results enhance our conviction for a differentiated clinical and logistics profile from the SARS-CoV-2 vaccine candidate ‘2373,\" the analyst said.\nShowing efficacy against new strains in two Phase 3 clinical trials, rather than extrapolating potential efficacy from a neutralizing antibody assay conducted in a petri dish, differentiates NVX-CoV2373 from other vaccines that have emergency use authorization, he said.\nThis profile, according to Cantor reduces regulatory/ commercial risk for the ‘2373 SARS-CoV-2 prophylactic vaccine candidate and, with positive Phase 3 data for NanoFlu reported in March 2020, should raise the profile for Novavax's platform as a whole.\nVaccine Safety Data:Pfizer-BioNTech's vaccine showed a favorable tolerability and safety profile, with the most common adverse events from BNT162b2 being transient, mild to moderate pain at the injection site, fatigue and headache, and these generally resolved within two days.\nFor Moderna, the most common adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.\nPreliminary safety data from Novavax's trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups.\nIn assessing reactogenicity seven days after dose one and dose two, injection site pain and tenderness, generally mild to moderate in severity, were the most common local symptoms, lasting less than three days. Fatigue, headache and muscle pain were the most common systemic symptoms, lasting less than two days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":187,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":691440727,"gmtCreate":1640232570462,"gmtModify":1640232570462,"author":{"id":"3574390258610228","authorId":"3574390258610228","name":"FatPenguin","avatar":"https://static.tigerbbs.com/61bcb8fe103d5050809234ff760d540b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574390258610228","idStr":"3574390258610228"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691440727","repostId":"2193150111","repostType":4,"isVote":1,"tweetType":1,"viewCount":1225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":168450877,"gmtCreate":1623981599499,"gmtModify":1634024776952,"author":{"id":"3574390258610228","authorId":"3574390258610228","name":"FatPenguin","avatar":"https://static.tigerbbs.com/61bcb8fe103d5050809234ff760d540b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574390258610228","idStr":"3574390258610228"},"themes":[],"htmlText":"Moon","listText":"Moon","text":"Moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168450877","repostId":"1167804746","repostType":4,"isVote":1,"tweetType":1,"viewCount":37,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161327369,"gmtCreate":1623906268151,"gmtModify":1634026020023,"author":{"id":"3574390258610228","authorId":"3574390258610228","name":"FatPenguin","avatar":"https://static.tigerbbs.com/61bcb8fe103d5050809234ff760d540b","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574390258610228","idStr":"3574390258610228"},"themes":[],"htmlText":"Wtonks","listText":"Wtonks","text":"Wtonks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/161327369","repostId":"1133173445","repostType":4,"repost":{"id":"1133173445","pubTimestamp":1623899282,"share":"https://www.laohu8.com/m/news/1133173445?lang=&edition=full","pubTime":"2021-06-17 11:08","market":"us","language":"en","title":"Why a crash in meme stocks AMC and GameStop looks more likely now","url":"https://stock-news.laohu8.com/highlight/detail?id=1133173445","media":"MarketWatch","summary":"Heavy insider selling is a warning sign that a stock’s price is inflated.\n\nCould insider sales of me","content":"<blockquote>\n Heavy insider selling is a warning sign that a stock’s price is inflated.\n</blockquote>\n<p>Could insider sales of meme stocks signal a coming crash in their share price? The empirical research suggests the answer is yes.</p>\n<p>The substantial stock sales by directors of GameStop GME, +0.21% and AMC Entertainment Holdings AMC, -6.54% didn’t surprise most rational investors. It’s clear that the current prices of these and other meme stocks are vastly inflated. In fact, investors should have seen AMC’s issuing new shares at its bloated price to raise capital as a warning sign.</p>\n<p>Critics might lambaste the opportunism of such insider selling, citing corporate governance gurus encouraging director ownership to align interests with public shareholders. But who can blame them? What is surprising is that more outside shareholders haven’t taken the signal to sell. It’s common for savvy investors to scan insider purchases and sales for signs of good or bad news ahead. Aggregate insider trading levels presage total stock returns for up to two years, according to the research of University of Michigan finance professor Nejat Seyhun, author of Investment Intelligence from Insider Trading.</p>\n<p>That said, some insider trades contain no signal at all, as directors buy when required to maintain mandatory ownership levels and sell when they need cash or to diversify investments. Moreover, insiders face reputational and legal risks when trading, so are careful not to signal hoarding good or bad news, lest they veer into unethical or illegal insider trading.</p>\n<p>But these meme-stock cases seem clearer. At AMC, for instance, many directors all sold around the same time in large numbers, near the company’s recent stock offering. Research by Durham University accounting professor Guanming He and colleagues indicates that the presence of concentrated insider stock-selling is associated with an increase in stock-price crash risk. That stands to reason: insiders know more than outsiders, whether investors, strategists or economists.</p>\n<p>Of course, no one can discern the fickle features of markets that precipitate reversals. But He’s research supports the view that insiders’ anticipation of future stock-price crash risk — from whatever source — does lead them to trim their holdings. In particular, the evidence is that insider sales are associated with 15-month-ahead crash risk.</p>\n<p>Such research may be particularly meaningful in the bizarre context of meme stocks. Compared to conventional stock trading, insiders are poised to make greater profits trading meme stocks and their trades are more informative given the greater degree of noise trading by uninformed traders.</p>\n<p>Research on past outcomes is no guarantee of future results, but together with common sense and an appreciation that all bubbles eventually burst, I’d be willing to place my own bets. The 15-month time frame would put the bursting of the GameStop bubble in the first quarter of 2022 and AMC around the third quarter. I’d certainly take both bets before I bought either stock.</p>","source":"market_watch","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why a crash in meme stocks AMC and GameStop looks more likely now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy a crash in meme stocks AMC and GameStop looks more likely now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 11:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/why-a-crash-in-meme-stocks-amc-and-gamestop-looks-more-likely-now-11623810848?siteid=yhoof2><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Heavy insider selling is a warning sign that a stock’s price is inflated.\n\nCould insider sales of meme stocks signal a coming crash in their share price? The empirical research suggests the answer is ...</p>\n\n<a href=\"https://www.marketwatch.com/story/why-a-crash-in-meme-stocks-amc-and-gamestop-looks-more-likely-now-11623810848?siteid=yhoof2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMC":"AMC院线","GME":"游戏驿站"},"source_url":"https://www.marketwatch.com/story/why-a-crash-in-meme-stocks-amc-and-gamestop-looks-more-likely-now-11623810848?siteid=yhoof2","is_english":true,"share_image_url":"https://static.laohu8.com/599a65733b8245fcf7868668ef9ad712","article_id":"1133173445","content_text":"Heavy insider selling is a warning sign that a stock’s price is inflated.\n\nCould insider sales of meme stocks signal a coming crash in their share price? The empirical research suggests the answer is yes.\nThe substantial stock sales by directors of GameStop GME, +0.21% and AMC Entertainment Holdings AMC, -6.54% didn’t surprise most rational investors. It’s clear that the current prices of these and other meme stocks are vastly inflated. In fact, investors should have seen AMC’s issuing new shares at its bloated price to raise capital as a warning sign.\nCritics might lambaste the opportunism of such insider selling, citing corporate governance gurus encouraging director ownership to align interests with public shareholders. But who can blame them? What is surprising is that more outside shareholders haven’t taken the signal to sell. It’s common for savvy investors to scan insider purchases and sales for signs of good or bad news ahead. Aggregate insider trading levels presage total stock returns for up to two years, according to the research of University of Michigan finance professor Nejat Seyhun, author of Investment Intelligence from Insider Trading.\nThat said, some insider trades contain no signal at all, as directors buy when required to maintain mandatory ownership levels and sell when they need cash or to diversify investments. Moreover, insiders face reputational and legal risks when trading, so are careful not to signal hoarding good or bad news, lest they veer into unethical or illegal insider trading.\nBut these meme-stock cases seem clearer. At AMC, for instance, many directors all sold around the same time in large numbers, near the company’s recent stock offering. Research by Durham University accounting professor Guanming He and colleagues indicates that the presence of concentrated insider stock-selling is associated with an increase in stock-price crash risk. That stands to reason: insiders know more than outsiders, whether investors, strategists or economists.\nOf course, no one can discern the fickle features of markets that precipitate reversals. But He’s research supports the view that insiders’ anticipation of future stock-price crash risk — from whatever source — does lead them to trim their holdings. In particular, the evidence is that insider sales are associated with 15-month-ahead crash risk.\nSuch research may be particularly meaningful in the bizarre context of meme stocks. Compared to conventional stock trading, insiders are poised to make greater profits trading meme stocks and their trades are more informative given the greater degree of noise trading by uninformed traders.\nResearch on past outcomes is no guarantee of future results, but together with common sense and an appreciation that all bubbles eventually burst, I’d be willing to place my own bets. The 15-month time frame would put the bursting of the GameStop bubble in the first quarter of 2022 and AMC around the third quarter. I’d certainly take both bets before I bought either stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":56,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}